Adicet Bio has received Fast Track Designation from the FDA for its therapy candidate, ADI-270. This candidate is aimed at patients suffering from metastatic/advanced clear cell renal cell carcinoma (ccRCC) who have already undergone specific treatments.

ADI-270 is an "off-the-shelf" gamma delta CAR T-cell therapy that targets CD70-positive cancers. It is engineered with a third-generation CAR design targeting CD70, using CD27 as the binding factor. It is further strengthened with a dominant negative form of the transforming growth factor-β receptor II (dnTGFβRII), making it a potentially effective treatment for patients with metastatic/advanced ccRCC and other patients with CD70+ tumors.

Adicet Bio is a biotechnology company that develops allogeneic gamma delta T-cell therapies for cancer and autoimmune diseases. The company’s approach involves engineering gamma delta T-cells with chimeric antigen receptors (CARs) to create off-the-shelf therapies to provide durable and effective treatments. Its leading product candidate, ADI-001, targets CD20 to treat relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma and autoimmune diseases. Another significant candidate is ADI-270 which targets renal cell carcinoma and other CD70+ solid tumors.